Other languages HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.85 ^USD	+11.11%		+4.95%	+4.94%

Apr. 10	HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200	CI
Mar. 22	HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200	Apr. 10
HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22
HOOKIPA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 22
HOOKIPA Pharma to Cut 30% of Workforce in Restructuring	Jan. 29
HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024	Jan. 16
Top Premarket Gainers	Dec. 21
HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024	Dec. 01
HOOKIPA Pharma's HIV Vaccine Candidate HB-500 Receives FDA Clearance for Investigational New-Drug Application	Nov. 20
Hookipa Pharma Announces FDA Clearance of Its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus	Nov. 20
HOOKIPA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
HOOKIPA Pharma Inc. Presents Positive Biomarker and Translational Data on HB-200 Monotherapy At Society for Immunotherapy of Cancer 2023	Nov. 03
HOOKIPA Pharma Says Head, Neck Cancer Phase 2 Study of Therapy Combination Showed 42% Objective Response Rate	23-10-23
Hookipa Pharma Inc. Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023	23-10-22
HOOKIPA Pharma Operations Chief Christine Baker Resigns	23-10-20
HOOKIPA Pharma Inc. Announces Resignation of Christine Baker as Chief Operating Officer, Leaving on January 15, 2024	23-10-20
HOOKIPA Pharma Inc. Announces Publication of Preclinical Data of Hepatitis B Virus Therapeutic Vaccine Developed in Collaboration with Gilead Sciences	23-10-18
HOOKIPA Pharma Inc. Announces Management Changes	23-09-13
HOOKIPA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
HOOKIPA Pharma Prices $50 Million Public Offering of Common Stock, Preferred Stock	23-06-01
HOOKIPA Pharma Inc. Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with Hpv16+ Head and Neck Cancers	23-05-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages HOOKIPA Pharma Inc.

Equities

HOOK

US43906K1007

Other languages

Filters